Precocious puberty

Puberty occurring at an unusually early age

Medical condition

Precocious puberty

Other names| Early puberty
Specialty| Gynecology, andrology, endocrinology
Causes| Idiopathic, brain tumor

In medicine, precocious puberty is puberty occurring at an unusually early age. In most cases, the process is normal in every aspect except the unusually early age and simply represents a variation of normal development. There is early development of secondary sex characters and gametogenesis also starts earlier. Precocious puberty is of two types: true precocious puberty and pseudoprecocious puberty. In a minority of children with precocious puberty, the early development is triggered by a disease such as a tumor or injury of the brain.[1]

Even when there is no underlying disease, unusually early puberty can have adverse effects on social behavior and psychological development (having more mature knowledge than one's peers, feeling inadequate, trying to attend and establish friendships with older people, depression). Affected children also face shorter adult height potential and possible lifelong health risks. Central precocious puberty can be treated by suppressing the pituitary hormones that induce sex steroid production. The opposite condition is delayed puberty.[2][3]

The term is used with several slightly different meanings that are usually apparent from the context. In its broadest sense, and often simplified as early puberty, "precocious puberty" sometimes refers to any physical sex hormone effect, due to any cause, occurring earlier than the usual age, especially when it is being considered as a medical problem. Stricter definitions of "precocity" may refer only to central puberty starting before a statistically specified age based on percentile in the population (e.g., 2.5 standard deviations below the population mean),[4] on expert recommendations of ages at which there is more than a negligible chance of discovering an abnormal cause, or based on opinion as to the age at which early puberty may have adverse effects. A common definition for medical purposes is onset before 8 years in girls or 9 years in boys.[5]

## Causes

[edit]

Early pubic hair, breast, or genital development may result from natural early maturation or from several other conditions.

### Central

[edit]

If the cause can be traced to the hypothalamus or pituitary, the cause is considered central. Other names for this type are complete or true precocious puberty.[6]

Causes of central precocious puberty can include:

* hypothalamic hamartoma produces pulsatile gonadotropin-releasing hormone (GnRH)
* Langerhans cell histiocytosis
* McCune–Albright syndrome

Central precocious puberty can also be caused by brain tumors, infection (most commonly tuberculous meningitis, especially in developing countries), trauma, hydrocephalus, and Angelman syndrome.[7] Precocious puberty is associated with advancement in bone age, which leads to early fusion of epiphyses, thus resulting in reduced final height and short stature.[8]

Adrenocortical oncocytomas are rare with mostly benign and nonfunctioning tumors. There have been only three cases of functioning adrenocortical oncocytoma that have been reported up until 2013. Children with adrenocortical oncocytomas will present with "premature pubarche, clitoromegaly, and increased serum dehydroepiandrosterone sulfate and testosterone" which are some of the presentations associated with precocious puberty.[9][10]

Precocious puberty in girls begins before the age of 8. The youngest mother on record is Lina Medina, who gave birth at the age of either 5 years, 7 months and 17 days[11] or 6 years 5 months as mentioned in another report.[12]

"Central precocious puberty (CPP) was reported in some patients with suprasellar arachnoid cysts (SAC), and SCFE (slipped capital femoral epiphysis) occurs in patients with CPP because of rapid growth and changes of growth hormone secretion."[13]

If no cause can be identified, it is considered idiopathic or constitutional.

### Peripheral

[edit]

Secondary sexual development induced by sex steroids from other abnormal sources is referred to as peripheral precocious puberty or precocious pseudopuberty. It typically presents as a severe form of disease with children. Symptoms are usually as a sequelae from adrenal hyperplasia (because of 21-hydroxylase deficiency or 11-beta hydroxylase deficiency, the former being more common), which includes but is not limited to hypertension, hypotension, electrolyte abnormalities, ambiguous genitalia in females, signs of virilization in females. Blood tests will typically reveal high level of androgens with low levels of cortisol.

Causes can include:

* Endogenous sources
* Gonadal tumors (such as arrhenoblastoma)
* Adrenal tumors
* Germ cell tumor[14][15]
* Congenital adrenal hyperplasia
* McCune–Albright syndrome
* Silver–Russell syndrome
* Familial male-limited precocious puberty (testotoxicosis)
* Exogenous hormones
* Environmental exogenous hormones
* As treatment for another condition

### Isosexual and heterosexual

[edit]

Generally, patients with precocious puberty develop phenotypically appropriate secondary sexual characteristics. This is called isosexual precocity.[16]

In some cases, a patient may develop characteristics of the opposite sex. For example, a male may develop breasts and other feminine characteristics, while a female may develop a deepened voice and facial hair. This is called heterosexual or contrasexual precocity. It is very rare in comparison to isosexual precocity and is usually the result of unusual circumstances. As an example, children with a very rare genetic condition called aromatase excess syndrome – in which exceptionally high circulating levels of estrogen are present – usually develop precocious puberty. Males and females are hyper-feminized by the syndrome.[16] The "opposite" case would be the hyper-masculinisation of both male and female patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, in which there is an excess of androgens. Thus, in the aromatase excess syndrome the precocious puberty is isosexual in females and heterosexual in males, whilst in the CAH it is isosexual in males and heterosexual in females.[citation needed]

### Research

[edit]

Although the causes of early puberty are still somewhat unclear, girls who have a high-fat diet and are not physically active or are obese are more likely to physically mature earlier.[17][18][19] "Obese girls, defined as at least 10 kilograms (22 pounds) overweight, had an 80 percent chance of developing breasts before their ninth birthday and starting menstruation before age 12 – the western average for menstruation is about 12.7 years."[19] In addition to diet and exercise habits, exposure to chemicals that mimic estrogen (known as xenoestrogens) is another possible cause of early puberty in girls. Bisphenol A, a xenoestrogen found in hard plastics, has been shown to affect sexual development.[20] "Factors other than obesity, however, perhaps genetic and/or environmental ones, are needed to explain the higher prevalence of early puberty in black versus white girls."[18] While more girls are increasingly entering puberty at younger ages, new research indicates that some boys are actually starting later (delayed puberty).[21][22] "Increasing rates of obese and overweight children in the United States may be contributing to a later onset of puberty in boys, say researchers at the University of Michigan Health System."[22]

High levels of beta-hCG in serum and cerebrospinal fluid observed in a 9-year-old boy suggest a pineal gland tumor. The tumor is called a chorionic gonadotropin secreting pineal tumor. Radiotherapy and chemotherapy reduced tumor and beta-hCG levels normalized.[23]

In a study using neonatal melatonin on rats, results suggest that elevated melatonin could be responsible for some cases of early puberty.[24]

Familial cases of idiopathic central precocious puberty (ICPP) have been reported, leading researchers to believe there are specific genetic modulators of ICPP. Mutations in genes such as LIN28,[25][26] and LEP and LEPR, which encode leptin and the leptin receptor,[27] have been associated with precocious puberty. The association between LIN28 and puberty timing was validated experimentally in vivo, when it was found that mice with ectopic over-expression of LIN28 show an extended period of pre-pubertal growth and a significant delay in puberty onset.[28]

Mutations in the kisspeptin (KISS1) and its receptor, KISS1R (also known as GPR54), involved in GnRH secretion and puberty onset, are also thought to be the cause for ICPP[29][30] However, this is still a controversial area of research, and some investigators found no association of mutations in the LIN28 and KISS1/KISS1R genes to be the common cause underlying ICPP.[31]

The gene MKRN3, which is a maternally imprinted gene, was first cloned by Jong et al. in 1999. MKRN3 was originally named Zinc finger protein 127. It is located on human chromosome 15 on the long arm in the Prader-Willi syndrome critical region2, and has since been identified as a cause of premature sexual development or CPP.[32] The identification of mutations in MKRN3 leading to sporadic cases of CPP has been a significant contribution to better understanding the mechanism of puberty.[33] MKRN3 appears to act as a "brake" on the central hypothalamic-pituitary access. Thus, loss of function mutations of the protein allow early activation of the GnRH pathway and cause phenotypic CPP. Patients with a MKRN3 mutation all display the classic signs of CCP including early breast and testes development, increased bone aging and elevated hormone levels of GnRH and LH.[34]

## Diagnosis

[edit]

Studies indicate that breast development in girls and the appearance of pubic hair in both girls and boys are starting earlier than in previous generations.[18][35][36] As a result, "early puberty" in children as young as 8 and 9 is no longer considered abnormal, particularly with girls. Although it is not considered as abnormal, it may be upsetting to parents[21][37] and can be harmful to children who mature physically at a time when they are immature mentally.[38]

No age reliably separates normal from abnormal processes in children, but the following age thresholds for evaluation are thought to minimize the risk of missing a significant medical problem:

* Breast development in boys before appearance of pubic hair or testicular enlargement
* Pubic hair or genital enlargement (gonadarche) in boys with onset before 9 years
* Pubic hair (pubarche) before 8 or breast development (thelarche) in girls with onset before 7 years
* Menstruation (menarche) in girls before 10 years

Medical evaluation is sometimes necessary to recognize the few children with serious conditions from the majority who have entered puberty early but are still medically normal. Early sexual development warrants evaluation because it may:

* induce early bone maturation and reduce eventual adult height
* indicate the presence of a tumour or other serious problem
* cause the child, particularly a girl, to become an object of adult sexual interest.[19][39][40]

## Treatment

[edit]

One possible treatment is with anastrozole. GnRH agonists, including histrelin, triptorelin, or leuprorelin, are other possible treatments. Non-continuous use[clarification needed] of GnRH agonists stimulates the pituitary gland to release follicle stimulating hormone (FSH) and luteinizing hormone (LH).[why?][41] Triptorelin depot is widely used to treat central precocious puberty (CPP) in children.[42]

Puberty blockers work by stabilizing puberty symptoms, decreasing growth velocity, and slowing skeletal maturation.[43] The outcomes of treatment are assessed in terms of height, reproduction, metabolic, and psychosocial measures. The most pronounced effects on height have been seen in children experiencing the onset of puberty before 6 years of age; however there is variability in height outcomes across studies which can be attributed to varying study designs, time of symptom presentation, and time of treatment termination.[44] A study investigating the effects of puberty blockers on reproductive health showed no significant difference in the number of irregular menstrual cycles, pregnancies, or pregnancy outcomes between women who received treatment for precocious puberty and those who opted out of treatment.[45] Individuals with precocious puberty, early adrenarche, and early normal puberty show less stress after treatment compared to individuals without preexisting developmental conditions.[46]

Blockers are also used in the treatment of central precocious puberty resulting from conditions like hypothalamic hamartomas or congenital adrenal hyperplasia, where early onset of puberty is a symptom. Additionally, puberty blockers can be prescribed for children with severe forms of idiopathic short stature, allowing for more time for growth before the closure of growth plates.[47]

In the USA, since 1993, the US Food and Drug Administration (FDA) has supported the use of puberty blockers to treat precocious puberty.[48] Currently under FDA regulation the use of puberty blockers is considered on-label for the treatment of central precocious puberty.[49]][50]

For years, the FDA, Endocrine Society, American Academy of Pediatrics(AAP) and many other pediatric associations have supported the use of Gonadotropin-releasing hormone analogs(GnRHas) in central precocious puberty (CPP).[51]

In 2009, the Lawson Wilkins Pediatric Endocrine Society and European Society for Pediatric Endocrinology published a consensus statement highlighting the effectiveness of Gonadotropin-releasing hormone analogs(GnRHas) in early onset central precocious puberty.[52] They confirmed that the use of Gonadotropin-releasing hormone analogs(GnRHas) has had a positive effect on increasing adult height.[52][53] However these Endocrine Societies believe additional research should be conducted before routinely suggesting GnRHAs for other conditions.[52] There is still some uncertainty surrounding the effectiveness of GnRHas when utilized for other conditions.

Overall, puberty blockers have demonstrated an excellent safety and efficacy profile in the treatment of precocious puberty.

### Side effects

[edit]

The most common side effects reported include nonspecific headaches, hot flashes, and implant-related skin reactions.[54]

A systematic review of studies investigating the long-term effects of treating precocious puberty with GnRH agonists found that bone mineral density decreases during treatment but normalizes afterward, with no lasting effects on peak bone mass.[55]

## Prognosis

[edit]

Early puberty is posited to put girls at higher risk of sexual abuse;[19][40] however, a causal relationship is, as yet, inconclusive.[40] Early puberty also puts girls at a higher risk for teasing or bullying, mental health disorders and short stature as adults.[19][39][56] Girls as young as 8 are increasingly starting to menstruate, develop breasts and grow pubic and underarm hair; these "biological milestones" typically occurred only at 13 or older in the past. African-American girls are especially prone to early puberty.[18]

Though boys face fewer problems from early puberty than girls do, early puberty is not always positive for boys. Early sexual maturation in boys can be accompanied by increased aggressiveness due to the surge of pubertal hormones.[57] Because they appear older than their peers, pubescent boys may face increased social pressure to conform to adult norms; society may view them as more emotionally advanced, although their cognitive and social development may lag behind their physical development.[57] Studies have shown that early-maturing boys are more likely to be sexually active and are more likely to participate in risky behaviors.[58]

## History

[edit]

Pubertas praecox is the Latin term used by physicians from the 1790s onward. Various hypotheses and inferences on pubertal (menstrual, procreative) timing are attested since ancient times, which, well into early modernity were explained on the basis of temperamental, humoral and Jungian "complexional" causes, or general or local "plethora" (blood excess).[59]

## See also

[edit]

* Acceleration (human development)
* Heterochrony: Paedomorphosis
* Secular trend: Biological anthropology
* Primary ovarian insufficiency

## References

[edit]

1. ^ "Precocious Puberty". KidsHealth. Retrieved 2013-09-09.
2. ^ Howard, S. R.; Dunkel, L. (2018). "The Genetic Basis of Delayed Puberty" (PDF). Neuroendocrinology. 106 (3): 283–291\. doi:10.1159/000481569. PMID 28926843. S2CID 4772278.
3. ^ Klein, D. A.; Emerick, J. E.; Sylvester, J. E.; Vogt, K. S. (November 2017). "Disorders of Puberty: An Approach to Diagnosis and Management". American Family Physician. 96 (9): 590–599\. PMID 29094880.
4. ^ precocious+puberty at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
5. ^ "default - Stanford Children's Health". www.stanfordchildrens.org. Retrieved 2021-02-16.
6. ^ David Gardner, Dolores Shoback. Basic And Clinical Endocrinology. McGraw-Hill Medical; 2011. 9th Edition. Pg. 550
7. ^ Dickerman, R. D.; Stevens, Q. E.; Steide, J. A.; Schneider, S. J. (2004). "Precocious puberty associated with a pineal cyst: is it disinhibition of the hypothalamic-pituitary axis?". Neuro Endocrinology Letters. 25 (3): 173–175\. PMID 15349080.
8. ^ Kumar, Manoj; Mukhopadhyay, Satinath; Dutta, Deep (2015-01-15). "Challenges and controversies in diagnosis and management of gonadotropin dependent precocious puberty: An Indian perspective". Indian Journal of Endocrinology and Metabolism. 19 (2): 228–235\. doi:10.4103/2230-8210.149316. PMC 4319262. PMID 25729684.
9. ^ Subbiah, Sridhar; Nahar, Uma; Samujh, Ram; Bhansali, Anil (May 2013). "Heterosexual precocity: rare manifestation of virilizing adrenocortical oncocytoma". Annals of Saudi Medicine. 33 (3): 294–297\. doi:10.5144/0256-4947.2013.294. ISSN 0256-4947. PMC 6078526. PMID 23793435. "So far, in the pediatric age group, only three cases of functioning adrenocortical oncocytoma have been reported. We report a case of functioning adrenocortical oncocytoma in a 3 1/2-year-old female child who presented with premature pubarche, clitoromegaly, and increased serum dehydroepiandrosterone sulfate and testosterone. She was managed successfully with right adrenalectomy, and the tumor histology was consistent with adrenal oncocytoma."
10. ^ Santos-Silva, Rita; Bonito-Vítor, Artur; Campos, Miguel; Fontoura, Manuel (2014). "Gonadotropin-Dependent Precocious Puberty in an 8-Year-Old Boy with Leydig Cell Testicular Tumor". Hormone Research in Paediatrics. 82 (2): 133–137\. doi:10.1159/000358084. ISSN 1663-2818. PMID 24862970. S2CID 9961260.
11. ^ "Six decades later, world's youngest mother awaits aid". The Telegraph. August 27, 2002. Archived from the original on July 22, 2009. Retrieved April 13, 2016.
12. ^ "Little Mother". Time. December 16, 1957. Archived from the original on April 22, 2009. Retrieved January 9, 2008.
13. ^ Yamato, Fumiko; Takaya, Junji; Higashino, Hirohiko; Yamanouchi, Yasuo; Suehara, Hiroshi; Kobayashi, Yohnosuke (March 2005). "Slipped capital femoral epiphysis during the treatment of precocious puberty with a gonadotropin-releasing hormone-agonist: aetiological considerations". European Journal of Pediatrics. 164 (3): 173–174\. doi:10.1007/s00431-004-1578-7. PMID 15592875. S2CID 27162486.
14. ^ Masse, R. J.; Shaw, P. J.; Burgess, M. (2008). "Intracranial choriocarcinoma causing precocious puberty and cured with combined modality therapy". Journal of Paediatrics and Child Health. 29 (6): 464–467\. doi:10.1111/j.1440-1754.1993.tb03022.x. PMID 8286166. S2CID 21886832.
15. ^ Antoniazzi, F.; Zamboni, G. (2004). "Central precocious puberty: current treatment options". Paediatric Drugs. 6 (4): 211–231\. doi:10.2165/00148581-200406040-00002. PMID 15339200. S2CID 21330464.
16. ^ a b Jarzabek-Bielecka, G; Warchoł-Biedermann, K; Sowińska, E; Wachowiak-Ochmańska, K (April 2011). "[Precocious puberty]". Ginekologia Polska. 82 (4): 281–6\. PMID 21735696.
17. ^ (Tanner, 1990).
18. ^ a b c d Kaplowitz, P. B.; Slora, E. J.; Wasserman, R. C.; Pedlow, S. E.; Herman-Giddens, M. E. (2001). "Earlier onset of puberty in girls: relation to increased body mass index and race". Pediatrics. 108 (2): 347–353\. doi:10.1542/peds.108.2.347. PMID 11483799.
19. ^ a b c d e McKenna, Phil (2007-03-05). "Childhood obesity brings early puberty for girls". New Scientist. Archived from the original on 2008-04-19. Retrieved 2010-05-22.
20. ^ Libertun, C.; Lux-Lantos, V.; Bianchi, M.; Fernández, M. (2009). "Neonatal Exposure to Bisphenol a Alters Reproductive Parameters and Gonadotropin Releasing Hormone Signaling in Female Rats". Environmental Health Perspectives. 117 (5): 757–762\. Bibcode:2009EnvHP.117..757F. doi:10.1289/ehp.0800267. PMC 2685838. PMID 19479018.
21. ^ a b Cooney, Elizabeth (2010-02-11). "Puberty gap: Obesity splits boys, girls. Adolescent males at top of the BMI chart may be delayed". NBC News. Archived from the original on January 11, 2016. Retrieved 2010-05-22.
22. ^ a b "Childhood Obesity May Contribute to Later Onset of Puberty for Boys". Science Daily. February 2010. Retrieved 2010-05-22.
23. ^ Kuo, H. C.; Sheen, J. M.; Wu, K. S.; Wei, H. H.; Hsiao, C. C. (2006). "Precocious puberty due to human chorionic gonadotropin-secreting pineal tumor". Chang Gung Medical Journal. 29 (2): 198–202\. PMID 16767969.
24. ^ Esouifino, A. I.; Villanúa, M. A.; Agrasal, C. (1987). "Effect of neonatal melatonin administration on sexual development in the rat". Journal of Steroid Biochemistry. 27 (4–6): 1089–1093\. doi:10.1016/0022-4731(87)90194-4. PMID 3121932.4–6&rft.pages=1089-1093&rft.date=1987&rft_id=info:doi/10.1016/0022-4731(87)90194-4&rft_id=info:pmid/3121932&rft.aulast=Esouifino&rft.aufirst=A.+I.&rft.au=Villanúa,+M.+A.&rft.au=Agrasal,+C.&rfr_id=info:sid/en.wikipedia.org:Precocious+puberty" class="Z3988">
25. ^ Park, Sung Won; Lee, Seung-Tae; Sohn, Young Bae; Cho, Sung Yoon; Kim, Se-Hwa; Kim, Su Jin; Kim, Chi Hwa; Ko, Ah-Ra; Paik, Kyung-Hoon; Kim, Jong-Won; Jin, Dong-Kyu (1 January 2012). "polymorphisms are associated with central precocious puberty and early puberty in girls". Korean Journal of Pediatrics. 55 (10): 388–92\. doi:10.3345/kjp.2012.55.10.388. PMC 3488615. PMID 23133486.
26. ^ Ong, Ken K; Elks, Cathy E; Li, Shengxu; Zhao, Jing Hua; Luan, Jian'an; Andersen, Lars B; Bingham, Sheila A; Brage, Soren; Smith, George Davey; Ekelund, Ulf; Gillson, Christopher J; Glaser, Beate; Golding, Jean; Hardy, Rebecca; Khaw, Kay-Tee; Kuh, Diana; Luben, Robert; Marcus, Michele; McGeehin, Michael A; Ness, Andrew R; Northstone, Kate; Ring, Susan M; Rubin, Carol; Sims, Matthew A; Song, Kijoung; Strachan, David P; Vollenweider, Peter; Waeber, Gerard; Waterworth, Dawn M; Wong, Andrew; Deloukas, Panagiotis; Barroso, Inês; Mooser, Vincent; Loos, Ruth J; Wareham, Nicholas J (16 May 2009). "Genetic variation in LIN28B is associated with the timing of puberty". Nature Genetics. 41 (6): 729–733\. doi:10.1038/ng.382. PMC 3000552. PMID 19448623.
27. ^ Su, Pen-Hua; Yang, Shun-Fa; Yu, Ju-Shan; Chen, Suh-Jen; Chen, Jia-Yuh (15 February 2012). "Study of leptin levels and gene polymorphisms in patients with central precocious puberty". Pediatric Research. 71 (4–1): 361–367\. doi:10.1038/pr.2011.69. PMID 22391636.4–1&rft.pages=361-367&rft.date=2012-02-15&rft_id=info:doi/10.1038/pr.2011.69&rft_id=info:pmid/22391636&rft.aulast=Su&rft.aufirst=Pen-Hua&rft.au=Yang,+Shun-Fa&rft.au=Yu,+Ju-Shan&rft.au=Chen,+Suh-Jen&rft.au=Chen,+Jia-Yuh&rft_id=https://doi.org/10.1038%2Fpr.2011.69&rfr_id=info:sid/en.wikipedia.org:Precocious+puberty" class="Z3988">
28. ^ Zhu H, Shah S, Shyh-Chang N, Shinoda G, Einhorn WS, Viswanathan SR, Takeuchi A, Grasemann C, Rinn JL, Lopez MF, Hirschhorn JN, Palmert MR, Daley GQ (July 2010). "Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies". Nat Genet. 42 (7): 626–30\. doi:10.1038/ng.593. PMC 3069638. PMID 20512147.
29. ^ Teles, Milena Gurgel; Silveira, Leticia Ferreira Gontijo; Tusset, Cintia; Latronico, Ana Claudia (1 October 2011). "New genetic factors implicated in human GnRH-dependent precocious puberty: The role of kisspeptin system". Molecular and Cellular Endocrinology. 346 (1–2): 84–90\. doi:10.1016/j.mce.2011.05.019. PMID 21664234. S2CID 27207961.1–2&rft.pages=84-90&rft.date=2011-10-01&rft_id=https://api.semanticscholar.org/CorpusID:27207961#id-name=S2CID&rft_id=info:pmid/21664234&rft_id=info:doi/10.1016/j.mce.2011.05.019&rft.aulast=Teles&rft.aufirst=Milena+Gurgel&rft.au=Silveira,+Leticia+Ferreira+Gontijo&rft.au=Tusset,+Cintia&rft.au=Latronico,+Ana+Claudia&rfr_id=info:sid/en.wikipedia.org:Precocious+puberty" class="Z3988">
30. ^ Silveira, LG; Noel, SD; Silveira-Neto, AP; Abreu, AP; Brito, VN; Santos, MG; Bianco, SD; Kuohung, W; Xu, S; Gryngarten, M; Escobar, ME; Arnhold, IJ; Mendonca, BB; Kaiser, UB; Latronico, AC (May 2010). "Mutations of the KISS1 gene in disorders of puberty". The Journal of Clinical Endocrinology and Metabolism. 95 (5): 2276–80\. doi:10.1210/jc.2009-2421. PMC 2869552. PMID 20237166.
31. ^ Tommiska, Johanna; Sørensen, Kaspar; Aksglaede, Lise; Koivu, Rosanna; Puhakka, Lea; Juul, Anders; Raivio, Taneli (1 January 2011). "LIN28B, LIN28A, KISS1, and KISS1R in idiopathic central precocious puberty". BMC Research Notes. 4 (1): 363. doi:10.1186/1756-0500-4-363. PMC 3184284. PMID 21939553.
32. ^ Abreu AP, Dauber A, Macedo DB, Noel SD, Brito VN, Gill JC, Cukier P, Thompson IR, Navarro VM, Gagliardi PC, et al. (2013). "Central precocious puberty caused by mutations in the imprinted gene MKRN3". N Engl J Med. 368 (26): 2467–2475\. doi:10.1056/nejmoa1302160. PMC 3808195. PMID 23738509.
33. ^ Macedo DB, Abreu AP, Reis AC, Montenegro LR, Dauber A, Beneduzzi D, Cukier P, Silveira LF, Teles MG, Carroll RS, et al. (2014). "Central precocious puberty that appears to be sporadic caused by paternally inherited mutations in the imprinted gene makorin ring finger 3". J Clin Endocrinol Metab. 99 (6): E1097–1103. doi:10.1210/jc.2013-3126. PMC 4037732. PMID 24628548.
34. ^ Abreu AP, Macedo DB, Brito VN, et al. (2015). "A new pathway in the control of the initiation of puberty: the MKRN3 gene". Journal of Molecular Endocrinology. 54 (3): R131 – R139. doi:10.1530/jme-14-0315. PMC 4573396. PMID 25957321.
35. ^ Zukauskaite, S.; Lasiene, D.; Lasas, L.; Urbonaite, B.; Hindmarsh, P. (2005). "Onset of breast and pubic hair development in 1231 preadolescent Lithuanian schoolgirls". Archives of Disease in Childhood. 90 (9): 932–936\. doi:10.1136/adc.2004.057612. PMC 1720558. PMID 15855182.
36. ^ Roberts, Michelle (2005-05-15). "Why puberty now begins at seven". BBC News. Retrieved 2010-05-22.
37. ^ Ritter, Jim (2000-08-02). "Parents worried by girls' earlier start of puberty". Chicago Sun-Times.
38. ^ Diana Zuckerman (2001). "Early Puberty in Girls". The Ribbon. Cornell University Program on Breast Cancer and Environmental Risk Factors. Retrieved 18 February 2018.
39. ^ a b (Stattin & Magnussion, 1990)
40. ^ a b c Mendle J, Leve L, Van Ryzin M, Natsuaki M (August 2013). "Linking Childhood Maltreatment With Girls' Internalizing Symptoms: Early Puberty as a Tipping Point". Journal of Research on Adolescence. 24 (3): 626–30\. doi:10.1111/jora.12075. PMC 4236856. PMID 25419091.
41. ^ Florence Comite; Cutler, Gordon B.; Rivier, Jean; Vale, Wylie W.; Loriaux, D. Lynn; Crowley, William F. (24 December 1981). "Short-Term Treatment of Idiopathic Precocious Puberty with a Long-Acting Analogue of Luteinizing Hormone-Releasing Hormone". New England Journal of Medicine. 305 (26): 1546–1550\. doi:10.1056/NEJM198112243052602. PMID 6458765.
42. ^ Bertelloni, Silvano; Mucaria, Cristina; Baroncelli, Giampiero I.; Peroni, Diego (July 2018). "Triptorelin depot for the treatment of children 2 years and older with central precocious puberty". Expert Review of Clinical Pharmacology. 11 (7): 659–667\. doi:10.1080/17512433.2018.1494569. ISSN 1751-2441. PMID 29957076.
43. ^ Latronico AC, Brito VN, Carel JC (March 2016). "Causes, diagnosis, and treatment of central precocious puberty". The Lancet. Diabetes & Endocrinology. 4 (3): 265–274\. doi:10.1016/S2213-8587(15)00380-0. PMID 26852255.
44. ^ Fuqua JS (June 2013). "Treatment and outcomes of precocious puberty: an update". The Journal of Clinical Endocrinology and Metabolism. 98 (6): 2198–2207\. doi:10.1210/jc.2013-1024. PMID 23515450.
45. ^ Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M, Papaefstathiou A, Lalioti N, Kanaka-Gantenbein C, Piaditis G, Chrousos GP, Dacou-Voutetakis C (January 2010). "The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study". The Journal of Clinical Endocrinology and Metabolism. 95 (1): 109–117\. doi:10.1210/jc.2009-0793. PMID 19897682.
46. ^ Menk TA, Inácio M, Macedo DB, Bessa DS, Latronico AC, Mendonca BB, Brito VN (May 2017). "Assessment of stress levels in girls with central precocious puberty before and during long-acting gonadotropin-releasing hormone agonist treatment: a pilot study". Journal of Pediatric Endocrinology & Metabolism. 30 (6): 657–662\. doi:10.1515/jpem-2016-0425. PMID 28599388.
47. ^ Carel JC, Léger J (May 2008). "Clinical practice. Precocious puberty". The New England Journal of Medicine. 358 (22): 2366–2377\. doi:10.1056/NEJMcp0800459. PMID 18509122.
48. ^ Benisek, Alexandra. "What Are Puberty Blockers?". WebMD. Retrieved 2024-08-01.
49. ^ Lopez CM, Solomon D, Boulware SD, Christison-Lagay E (October 2018). "Trends in the "Off-Label" Use of GnRH Agonists Among Pediatric Patients in the United States". Clinical Pediatrics. 57 (12): 1432–1435\. doi:10.1177/0009922818787260. PMID 30003804.
50. ^ "Proposed Talking Points to Oppose Gender-Affirming Care Criminalization Bills". apa.org. American Psychological Association. Archived from the original on 5 May 2021. Retrieved 11 October 2022.
51. ^ Kletter GB, Klein KO, Wong YY (May 2015). "A pediatrician's guide to central precocious puberty". Clinical Pediatrics. 54 (5): 414–424\. doi:10.1177/0009922814541807. PMID 25022947.
52. ^ a b c Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J, Deal S, de Vries L, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowitz P, Lahlou N, Lee MM, Lee P, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman D, Styne D, Tauber M, Wit JM (April 2009). "Consensus statement on the use of gonadotropin-releasing hormone analogs in children". Pediatrics. 123 (4): e752 – e762. doi:10.1542/peds.2008-1783. PMID 19332438.
53. ^ Chen M, Eugster EA (August 2015). "Central Precocious Puberty: Update on Diagnosis and Treatment". Paediatric Drugs. 17 (4): 273–281\. doi:10.1007/s40272-015-0130-8. PMC 5870137. PMID 25911294.
54. ^ Lewis KA, Eugster EA (September 2009). "Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty". Drug Design, Development and Therapy. 3: 1–5\. doi:10.2147/DDDT.S3298. PMC 2769233. PMID 19920916.
55. ^ Soliman, Ashraf T.; Alaaraj, Nada; De Sanctis, Vincenzo; Hamed, Noor; Alyafei, Fawzia; Ahmed, Shayma (5 December 2023). "Long-term health consequences of central precocious/early puberty (CPP) and treatment with Gn-RH analogue: a short update: Long term consequences of precocious puberty". Acta Biomedica: Atenei Parmensis. 94 (6): e2023222. doi:10.23750/abm.v94i6.15316. PMC 10734238. PMID 38054666.
56. ^ (Caspi et al.1993: Lanza and Collins, 2002)
57. ^ a b Garn, SM. Physical growth and development. In: Friedman SB, Fisher M, Schonberg SK, editors. Comprehensive Adolescent Health Care. St Louis: Quality Medical Publishing; 1992. Retrieved on 2009-02-20
58. ^ Susman, EJ; Dorn, LD; Schiefelbein, VL. Puberty, sexuality, and health. In: Lerner MA, Easterbrooks MA, Mistry J., editors. Comprehensive Handbook of Psychology. New York: Wiley; 2003. Retrieved on 2009-02-20
59. ^ Janssen, Diederik (2021). "Puer barbatus: Precocious Puberty in Early Modern Medicine". Journal of the History of Medicine and Allied Sciences. 76 (1): 20–52\. doi:10.1093/jhmas/jraa045. PMC 7737932. PMID 33186444.

Classification|

* ICD-11: 5A92
* ICD-10: E30.1, E22.8
* ICD-9-CM: 259.1
* OMIM: 176400
* MeSH: D011629
* DiseasesDB: 10519

|

External resources|

* MedlinePlus: 001168
* eMedicine: ped/1882

* v
* t
* e

Gonadal disorder

Ovarian|

* Polycystic ovary syndrome
* Premature ovarian failure
* Hyperthecosis

Testicular|

| Enzymatic|

* 5α-reductase 2 deficiency
* 17β-Hydroxysteroid dehydrogenase deficiency
* Aromatase excess syndrome

|

Androgen receptor|

* Androgen insensitivity syndrome
* Mild androgen insensitivity syndrome
* Partial androgen insensitivity syndrome
* Complete androgen insensitivity syndrome
* Familial male-limited precocious puberty

Other|

* Sertoli cell-only syndrome

General|

* Hypogonadism
* Delayed puberty
* Hypergonadism
* Precocious puberty
* Hypoandrogenism
* Hypoestrogenism
* Hyperandrogenism
* Hyperestrogenism
* Postorgasmic illness syndrome
* Cytochrome P450 oxidoreductase deficiency
* Cytochrome b5 deficiency
* Androgen-dependent condition
* Aromatase deficiency
* Estrogen insensitivity syndrome
* Hypergonadotropic hypogonadism
* Hypogonadotropic hypogonadism
* Fertile eunuch syndrome
* Estrogen-dependent condition
* Premature thelarche
* Gonadotropin insensitivity
* Hypergonadotropic hypergonadism

Authority control databases

National|

* United States
* Israel

Other|

* Yale LUX

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template